Skip to Content

New drug to combat “untreatable” global killer sepsis

A promising new drug to combat sepsis has been developed by researchers at The Australian National University (ANU), potentially saving millions of lives each year.

ANU Professor Christopher Parish and his team have been working on the drug for more than 10 years, with the drug being developed from compounds originally designed to fight cancer.

There are some 11 million sepsis-related deaths worldwide each year, according to The World Health Organization (WHO) – accounting for almost 20 per cent of all global deaths.

“There is a huge medical need for a treatment for sepsis. It is surprising how many people die from sepsis and the medical profession hasn’t yet found a treatment,” Professor Parish said.

“We hope that we can now treat the untreatable. This drug is very safe, and we are very excited about its potential use against sepsis.”

Sepsis is a dangerous, often fatal response to infection from many diseases – including COVID-19.

“Sepsis occurs when pathogens – usually bacteria but sometimes viruses – get out of control and the immune system tries to control them but overdoes the job and causes massive collateral damage,” Professor Parish said.

“Our drug stops patients from feeling very sick due to this uncontrolled collateral damage, a process that can result in multi-organ failure and death.”

The drug, initially developed on-site at ANU and further developed in collaboration with chemist Professor Mark von Itzstein from Griffith University, has passed Phase 1 clinical trials in healthy volunteers and is undergoing another Phase 1 trial in sepsis patients.

The development of the new drug was made possible after a discovery made by US researchers about a decade ago. They found a prominent family of proteins that interacts with DNA, called histones, are the cause of death by sepsis.

Histones are toxic because they can bind to the surface of cells and puncture holes in them – but they don’t know how to discriminate between bacteria, viruses and their own cells.

Since then, Professor Parish’s team has been working on a drug which neutralises histones.

“Normally histones are harmless, packaging DNA within cells, but outside cells they can be very toxic,” Professor Parish said.

“The drug binds to histones and stops them from punching holes in cell membranes.”  

The researchers say their new drug could help some people with COVID-19 – particularly those patients with sepsis-like symptoms in their lungs.

“We have spent 10 years developing this drug to treat sepsis and although not planned, we predict it may have some activity against COVID-19,” Professor Parish said.

“But sepsis will be here long after we get rid of COVID-19 – because it can come in all shapes and forms and a lot of pathogens can induce it.

“If this drug works as predicted, it should be a game changer in treating sepsis - one of the biggest challenges in 21st century medicine.”

Research on the compound published in Nature Communications today.

FOR INTERVIEW:

Professor Chris Parish
John Curtin School of Medical Research, ANU
T: 02 612 52604
M: 0413 721 599
E:christopher.parish@anu.edu.au

For media assistance, contact Rachel Curtis on 0459879726 or the ANU Media Team on +61 2 6125 7979 or at media@anu.edu.au  

About The Australian National University

ANU is a world-leading university in Australia’s capital city, Canberra. Our location points to our unique history, ties to the Australian Government and special standing as a resource for the Australian people.

Our focus on research as an asset, and an approach to education, ensures our graduates are in demand the world-over for their abilities to understand, and apply vision and creativity to addressing complex contemporary challenges.

The Australian National University
East Road, Acton
2601 Canberra